Loading data for IMDX — first visit, this takes a few seconds.

알림

Insight Molecular Diagnos... (IMDX)

NasdaqCM: IMDX · 실시간 가격 · USD

4.40

+0.12 (2.80%)

종가 기준: Aug 19, 2026, 4:34 PM

2.80% (1D)

데이터 없음

매수호가	n/a
시가총액	143.99M
매출 (ttm)	1.67M
순이익 (ttm)	-49.36M
베타	1.82
EPS (ttm)	-1.52
P/E (ttm)	n/a
선행 P/E	-5.24
P/B (ttm)	-6.74
P/S (ttm)	86.22
Earnings Date	Nov 9, 2026

매도호가	n/a
거래량	26,506
평균 거래량 (20일)	246,801
시가	4.29
전일 종가	4.28
일중 범위	4.25 - 4.46
52주 범위	2.33 - 8.51
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

IMDX 소개

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment...

[더 보기]

산업 Diagnostics & Research

섹터 Healthcare

IPO 일자 Dec 30, 2015

직원 수 55

상장 거래소 NasdaqCM

티커 IMDX

웹사이트 https://www.imdxinc.com

전체 기업 정보

재무 실적

2025년 Insight Molecular Diagnostics의 매출은 4.05M로, 전년 1.88M 대비 115.58% 증가했습니다. 순이익은 -50.22M로, -17.21% 감소했습니다.

재무제표

어닝 서프라이즈

Insight Molecular Diagnostics가 Aug 10, 2026에 분기 실적을 발표했습니다:

매출 $32K 예상치 하회 $0, 및 -98.50% 전년 대비 감소.

EPS -0.24 예상치 하회 -0.01, 및 20.00% 전년 대비 성장.

다음 실적 발표

Insight Molecular Diagnostics Inc.의 실적 발표 예정일은 Nov 9, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Moby

Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary

Moby summary of Insight Molecular Diagnostics Inc.'s Q2 2026 earnings call

1주 전 · MarketBeat

Oncocyte Q2 Earnings Call Highlights

Oncocyte (NASDAQ:IMDX) executives said they continue to target FDA marketing authorization for the GraftAssureDx kidney-transplant rejection test later this year, while preparing for a commercial laun...

2개월 전 · Insider Monkey

Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment

Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) is one of the high-growth micro-cap stocks to buy now. On June 11, Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) announced the online publication in...

3개월 전 · Simply Wall St.

How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission

Insight Molecular Diagnostics now sits under a refreshed analyst narrative, with a price target that has moved to US$12 per share alongside an updated fair value estimate of US$10.50. Analysts linking...

3개월 전 · Moby

Insight Molecular Diagnostics Inc. Q1 2026 Earnings Call Summary

Moby summary of Insight Molecular Diagnostics Inc.'s Q1 2026 earnings call

2 페이지 중 1